Organogenesis Holdings Inc (ORGO)
4.00
-0.43
(-9.71%)
USD |
NASDAQ |
Nov 14, 16:00
4.00
0.00 (0.00%)
After-Hours: 20:00
Organogenesis Holdings Enterprise Value: 560.89M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 560.89M |
| November 12, 2024 | 430.97M |
| November 11, 2024 | 437.60M |
| November 08, 2024 | 408.43M |
| November 07, 2024 | 405.78M |
| November 06, 2024 | 399.15M |
| November 05, 2024 | 376.62M |
| November 04, 2024 | 369.99M |
| November 01, 2024 | 342.15M |
| October 31, 2024 | 340.82M |
| October 30, 2024 | 356.73M |
| October 29, 2024 | 368.66M |
| October 28, 2024 | 364.68M |
| October 25, 2024 | 344.80M |
| October 24, 2024 | 354.08M |
| October 23, 2024 | 356.73M |
| October 22, 2024 | 384.57M |
| October 21, 2024 | 385.90M |
| October 18, 2024 | 392.52M |
| October 17, 2024 | 380.59M |
| October 16, 2024 | 404.46M |
| October 15, 2024 | 397.83M |
| October 14, 2024 | 383.24M |
| October 11, 2024 | 380.59M |
| October 10, 2024 | 358.05M |
| Date | Value |
|---|---|
| October 09, 2024 | 373.96M |
| October 08, 2024 | 369.99M |
| October 07, 2024 | 369.99M |
| October 04, 2024 | 381.92M |
| October 03, 2024 | 352.75M |
| October 02, 2024 | 351.43M |
| October 01, 2024 | 347.45M |
| September 30, 2024 | 352.75M |
| September 27, 2024 | 356.73M |
| September 26, 2024 | 347.45M |
| September 25, 2024 | 340.82M |
| September 24, 2024 | 359.38M |
| September 23, 2024 | 347.45M |
| September 20, 2024 | 348.77M |
| September 19, 2024 | 362.03M |
| September 18, 2024 | 351.43M |
| September 17, 2024 | 359.38M |
| September 16, 2024 | 352.75M |
| September 13, 2024 | 346.12M |
| September 12, 2024 | 319.61M |
| September 11, 2024 | 312.98M |
| September 10, 2024 | 312.98M |
| September 09, 2024 | 310.33M |
| September 06, 2024 | 301.05M |
| September 05, 2024 | 323.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
216.21M
Minimum
Mar 24 2023
2.971B
Maximum
May 03 2021
748.99M
Average
469.49M
Median
Enterprise Value Benchmarks
| Poseida Therapeutics Inc | 138.61M |
| NovaBay Pharmaceuticals Inc | 2.762M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 6.814M |
| Theriva Biologics Inc | -13.26M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.04M |
| Revenue (Quarterly) | 130.23M |
| Total Expenses (Quarterly) | 121.32M |
| EPS Diluted (Quarterly) | -0.13 |
| Gross Profit Margin (Quarterly) | 77.58% |
| Profit Margin (Quarterly) | -13.09% |
| Earnings Yield | -3.36% |
| Operating Earnings Yield | 2.23% |
| Normalized Earnings Yield | 0.0383 |